广生堂(300436) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥96,523,364.67, representing a year-on-year increase of 1.68% compared to ¥94,929,591.85 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥9,131,629.17, a significant decline of 615.90% from a profit of ¥1,770,052.55 in the previous year[4] - The net profit for Q1 2022 was a loss of CNY 11,085,643.29, compared to a profit of CNY 2,212,394.60 in Q1 2021, indicating a substantial decline[33] - The total comprehensive income for Q1 2022 was a loss of CNY 11,085,643.29, compared to a gain of CNY 2,212,394.60 in the same period last year[34] - Earnings per share (EPS) for Q1 2022 was -0.0575, down from 0.0126 in the same quarter last year[34] Cash Flow - The net cash flow from operating activities was -¥19,328,170.43, a decrease of 719.71% compared to a positive cash flow of ¥3,118,900.02 in the same period last year[8] - The net cash flow from operating activities was -19,328,170.43 CNY, compared to 3,118,900.02 CNY in the previous year[36] - The cash flow from operating activities showed a significant decline compared to the previous year[36] - Cash inflow from operating activities was CNY 114,180,960.32, slightly down from CNY 116,911,016.23 in the previous year[35] - Cash outflow from operating activities totaled CNY 133,509,130.75, an increase from CNY 113,792,116.21 year-on-year[35] - The net cash flow from investing activities was -63,575,697.42 CNY, a decrease from -30,839,510.51 CNY year-over-year[36] - The net cash flow from financing activities was 52,245,691.70 CNY, compared to -2,361,014.37 CNY in the previous year[36] - The company raised 25,100,000.00 CNY from minority shareholders during the financing activities[36] - The company obtained loans totaling 73,996,722.38 CNY, compared to 26,437,355.00 CNY in the previous year[36] - Cash outflow for debt repayment was 44,750,000.00 CNY, compared to 26,420,000.00 CNY in the previous year[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,493,133,372.25, an increase of 3.20% from ¥1,446,766,520.34 at the end of the previous year[4] - The company's current liabilities totaled 333,503,476.21 yuan, up from 302,312,036.51 yuan at the beginning of the year[29] - The company's long-term investments increased to 118,790,202.32 yuan from 99,977,002.91 yuan at the beginning of the year[28] - The company's total assets amounted to 1,493,133,372.25 yuan, an increase from 1,446,766,520.34 yuan at the beginning of the year[28] - The company's cash and cash equivalents decreased to 362,915,329.59 yuan from 393,573,505.74 yuan at the beginning of the year[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,156[11] - The largest shareholder, Fujian Aohua Group Co., Ltd., holds 14.05% of shares, totaling 22,368,651 shares, with 7,000,000 shares pledged[11] - The second-largest shareholder, Ye Liqing, holds 8.50% of shares, totaling 13,536,700 shares, with 10,152,525 shares unrestricted[11] - The company has a total of 44,765,674 restricted shares, with 18,777,000 shares released during the period[15] - The total number of shares held by the top ten unrestricted shareholders is 22,368,651 shares for Fujian Aohua Group Co., Ltd.[11] - The company has a total of 10,211,149 shares held by executive Li Guoping, which are subject to lock-up restrictions[14] - The company has not disclosed any other significant shareholder relationships beyond those mentioned[11] Research and Development - Research and development expenses increased by 63.68% to ¥25,840,978.81, up from ¥15,787,734.36, reflecting the company's commitment to innovative drug development[8] - The company is advancing the development of the innovative oral drug GST-HG171 for COVID-19, which has shown efficacy against various virus strains in preclinical models[16] - The company aims to expedite the research and development of GST-HG171 to contribute to pandemic control efforts[16] - The company has identified clinical candidates for GST-HG171 and is integrating resources for rapid development[16] - The company has initiated the Phase Ib clinical trial for the innovative hepatitis B treatment drug GST-HG141, showing good safety and efficacy results, and is preparing to advance to Phase II trials after obtaining necessary approvals[17] - The Phase I clinical trial for the new drug GST-HG151 targeting non-alcoholic fatty liver disease and liver fibrosis has successfully enrolled its first subject, with the trial conducted at Fujian Medical University[18] Investments and Contracts - The investment income from affiliated companies increased by 108.08% to ¥18,813,199.41, compared to ¥9,041,527.02 in the same period last year, driven by the growth in COVID-19 testing services[8] - The company signed a technical service contract with Fujian Ruitai Pharmaceutical Technology Co., Ltd., which will facilitate future drug commercialization and generate new business revenue[20] - The company has increased its investment in its wholly-owned subsidiary, Jin Tang Pharmaceutical, by 40 million yuan to support the construction of an integrated production base for raw materials[24] Tax and Compliance - The company received the High-tech Enterprise Certificate, allowing it to enjoy a reduced corporate income tax rate of 15% for three consecutive years from 2021 to 2023[25] - The company did not conduct an audit for the first quarter report[37]